Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial
In: Advances in therapy, Jg. 37 (2020-04-26), Heft 8
Online
unknown
Zugriff:
Allisartan isoproxil is a novel angiotensin II type 1 receptor antagonist that has been confirmed to lower blood pressure and protect target organs effectively. However, its role in improving endothelial function and vascular damage has not been investigated yet. Patients with initially diagnosed mild essential hypertension (BP ranging from 140/90 to 159/99 mmHg) with age from 25–75 years were randomly assigned 1:1 to either the allisartan group (allisartan 240 mg/day and lifestyle modification) or the lifestyle modification group and were followed up for 30 days. Flow-mediated dilation (FMD), brachial-ankle pulse wave velocity (baPWV) and endothelial microparticles (EMPs) were measured for evaluation of endothelial function and vascular damage. In addition, we enrolled 36 normotensive individuals as healthy control. Seventy-two mildly hypertensive patients were enrolled in this study. After 30 days of treatment, a significant increase in FMD was observed in the allisartan group (0.9 ± 0.7%, p
Titel: |
Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial
|
---|---|
Autor/in / Beteiligte Person: | Qiu, Yumin ; Zhou, Zhe ; Tao, Jun ; Zhang, Gaoxing ; Liu, Xing ; Zhang, Jianning ; Liu, Yuanya ; Fan, Yongqiang ; Wang, Zhichao |
Link: | |
Zeitschrift: | Advances in therapy, Jg. 37 (2020-04-26), Heft 8 |
Veröffentlichung: | 2020 |
Medientyp: | unknown |
ISSN: | 1865-8652 (print) |
Schlagwort: |
|
Sonstiges: |
|